Bayer: Speculative Value Beyond Litigation Pressures

Fotofantastika Bayer (OTCPK:BAYRY) stock is down 41% since I argued for a "Strong Buy" recommendation. Indeed, Bayer may have been my worst investment recommendation over the past 18 months. That said, I apologize to readers who may have felt encouraged to trade on my writing. Today I understand that my enthusiasm for the German Life Science giant may have been too strong, underestimating the intense weight of the Monsanto litigation headwinds. However, I still feel that there is value in Bayer, especially ...